Key facts
- Cardiosense’s last known valuation is $30.4M (Dec 2022).
- It has raised $15.2M across 1 recorded rounds; the latest was Early Stage VC ($9.1M) in Nov 2022.
- Notable investors include MedTech Innovator, Texas Medical Center, Matter (Consulting Services (B2B)), National Aeronautics and Space Administration, Hatteras Venture Partners — 16 tracked in total.
- Cardiosense has filed 1 Form D with the SEC, most recently Dec 2022 ($9.1M sold to 28 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Cardiosense
Funding rounds
1 roundsAbout Cardiosense
Developer of a digital biomarker platform designed to leverage multi-sensor devices and proprietary algorithms to detect early signs of disease. The company specializes in building and leveraging non-invasive sensors and artificial intelligence to facilitate cardiac monitoring, enabling healthcare professionals to analyze data and cardiac health signals and track patients' health.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2020
- Employees
- 40
- Website
- cardiosense.com/
- Ownership
- Privately Held (backing)
Cardiosense doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cardiosense shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cardiosense in its N-PORT filings yet. We sweep new filings monthly.